ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.26M | -1.42M | -2.40M | -2.76M | -2.83M |
| Total Depreciation and Amortization | -- | -7.80K | 1.70K | 10.40K | 2.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 153.90K | 283.10K | 160.70K | 162.50K | 310.60K |
| Change in Net Operating Assets | 331.00K | -78.20K | 1.59M | 676.70K | -1.26M |
| Cash from Operations | -1.77M | -1.22M | -644.40K | -1.91M | -3.78M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.00M | 3.04M | 828.00K | 0.00 | 2.67M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -147.10K | -407.90K | -180.10K | -- | -- |
| Cash from Financing | 1.85M | 2.63M | 647.80K | 0.00 | 2.67M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.60K | 1.41M | 3.40K | -1.91M | -1.10M |